MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • 2019 International Congress

    A Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson’s Disease Complicated By “OFF” Episodes

    F. Stocchi, K. Wilks, E. Peckham, M. de Pandis, K. Sciarappa, F. Agbo, R. Kleiman, D. Blum, B. Navia (Rome, Italy)

    Objective: To assess the effect of apomorphine sublingual film (APL130277; APL) on the QT interval in patients with Parkinson’s disease (PD) and “OFF” episodes participating…
  • 2019 International Congress

    Management of Akinesia in Parkinson’s Disease with Apomorphine Subcutaneous Injection

    F. Rakhimov, B. Sultanov (Tashkent, Uzbekistan)

    Objective: To assess the effect of apomorphine on time-to-ON in PD patients with morning akinesia. Background: In patients with motor fluctuations complicating Parkinson's disease (PD), delays in time-to-ON…
  • 2019 International Congress

    Establishing the first apomorphine treatment registry in Thailand: prospective data collection to inform optimal care of Parkinson’s disease patients

    R. Bhidayasiri, O. Phokaewvarangkul, K. Boonpang, T. Boonmongkol, Y. Thongchuam, N. Kantachadvanich, J. Sringean, P. Panyakaew, P. Jagota (Bangkok, Thailand)

    Objective: To establish a registry of PD patients in Thailand treated with subcutaneous apomorphine (APO) injection or infusion to allow prospective data collection from the…
  • 2019 International Congress

    The Effects of Apomorphine infusion on Head ptosis, a case report

    O. Skogar (Stockholm, Sweden)

    Objective: Sustained Effects of Apomorphine infusion on Head Ptosis, a case report Background: IntroductionHead ptosis (Hp) results from weakness of the neck extensor, or increased…
  • 2019 International Congress

    Dynamics of Device-based Treatments for Parkinson´s Disease in Germany from 2010 – 2017

    L. Tönges, D. Bartig, C. Krogias, D. Richter (Bochum, Germany)

    Objective: Analyze the patient profiles and dynamics of utilization of Continuous Subcutaneous Apomorphine Infusion (CSAI), Levodopa-carbidopa Intestinal Gel (LCIG), and Deep Brain Stimulation (DBS) for…
  • 2019 International Congress

    Treatment of subcutaneous nodules after subcutaneous infusion of apomorphine

    RWK. Borgemeester, GFH. Diercks, T. van Laar (Groningen, Netherlands)

    Objective: To evaluate the efficacy of 4 treatment modalities on apomorphine-induced subcutaneous nodules as compared to no treatment. Background: Subcutaneous nodules are the most common adverse events…
  • 2019 International Congress

    Apomorphine induced hemolytic anemia: A case report and literature review

    F. Hajiakhoundi, M. Motamed, M. Rohani, G. Shahidi (Tehran, Islamic Republic of Iran)

    Objective: To present a case of apomorphine induced hemolytic anemia Background: Drug induced immune hemolytic anemia (DIIHA) is a potentially lethal adverse reaction; It has…
  • 2019 International Congress

    Population Exposure-Response Models of Apomorphine Sublingual Film in Healthy Subjects and Patients With Parkinson’s Disease and “OFF” Episodes

    F. Agbo, Y. Chiu, S. Chapel, G. Galluppi, D. Blum, B. Navia (Fort Lee, NJ, USA)

    Objective: Exposure-response models were developed to characterize the relationship between apomorphine exposure and (1) efficacy using Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease…
  • 2019 International Congress

    Population Exposure-Response Modeling of the Effects of Apomorphine Sublingual Film on QTc in Patients With Parkinson’s Disease and “OFF” Episodes

    F. Agbo, Y. Chiu, S. Chapel, G. Galluppi, D. Blum, B. Navia (Fort Lee, NJ, USA)

    Objective: To characterize the relationship between plasma apomorphine concentrations and QTc (QT interval corrected for heart rate) in patients with Parkinson’s disease (PD) and “OFF”…
  • 2019 International Congress

    The Efficacy and Safety of Subcutaneous Apomorphine in Patients with Parkinson’s Disease: A Meta-Analysis Randomized Controlled Trials

    M. Azharuddin, M. Adil, P. Ghosh, M. Sharma (New Delhi, India)

    Objective: The objective of this study to evaluate the efficacy and safety of subcutaneous apomorphine for patients with Parkinson’s disease (PD). Background: Subcutaneous apomorphine has…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley